UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 333-283428-01

 

YD BIOPHARMA LIMITED

(Exact name of registrant as specified in its charter)

 

12F., No. 3, Xingnan St.,

Nangang Dist.,

Taipei City 115001, Taiwan

+(886) 2382-0330

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Ordinary shares, par value $0.10 per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)  
Rule 12g-4(a)(2)  
Rule 12h-3(b)(1)(i)  
Rule 12h-3(b)(1)(ii)  
Rule 15d-6  
Rule 15d-22(b)  

 

Approximate number of holders of record as of the certification or notice date: One

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, YD Biopharma Limited has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

  YD Biopharma Limited
Date: September 8, 2025    
  By: /s/ Ethan Shen
  Name:  Ethan Shen
  Title: Chief Executive Officer